Far Infrared Irradiation for Control, Management and Treatment of Amyotrophic Lateral Sclerosis (ALS)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by GAAD Medical Research Institute Inc..
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
GAAD Medical Research Institute Inc.
ClinicalTrials.gov Identifier:
NCT00673140
First received: May 6, 2008
Last updated: August 14, 2009
Last verified: August 2009

May 6, 2008
August 14, 2009
May 2008
May 2010   (final data collection date for primary outcome measure)
Therapy for ALS [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00673140 on ClinicalTrials.gov Archive Site
Rehabilitation of ALS patients [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Far Infrared Irradiation for Control, Management and Treatment of Amyotrophic Lateral Sclerosis (ALS)
Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Control, Management and Treatment of Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig's Disease

Amyotrophic Lateral Sclerosis (ALS, sometimes called Lou Gehrig's s Disease, or Maladie de Charcot) is a progressive, usually fatal, neurodegenerative disease caused by the degeneration of motor neurons, the nerve cells in the central nervous system that control voluntary muscle movement.

This study will investigate the use of far infrared radiation for the control, management and treatment of ALS.

As a motor neuron disease, ALS causes muscle weakness and atrophy throughout the body as both the upper and lower motor neurons degenerate, ceasing to send messages to muscles. Unable to function, the muscles gradually weaken, develop fasciculations (twitches) because of denervation, and eventually atrophy due to that denervation. The patient may ultimately lose the ability to initiate and control all voluntary movement except of the eyes.

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.

It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have ALS.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Amyotrophic Lateral Sclerosis
  • Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
    Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
    Other Name: Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
  • Radiation: Far infrared radiation
    Far infrared radiation at a frequency of 5 microns to 20 microns for 30 to 40 minutes per session.
Experimental: 1
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Interventions:
  • Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
  • Radiation: Far infrared radiation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
7
June 2010
May 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with ALS

Exclusion Criteria:

  • None
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00673140
GAAD-ALS-CTP1
Yes
Dr. Kwasi Donyina/Founder and President, GAAD Medical Research Institute Inc.
GAAD Medical Research Institute Inc.
Not Provided
Principal Investigator: Ken Nedd, M.D. GAAD Medical Research Institute Inc.
GAAD Medical Research Institute Inc.
August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP